Skip to main content

Citius Pharmaceuticals, Inc.

corporate_fare Company Profile

Citius Pharmaceuticals, Inc.

CTXR·NASDAQ·Life Sciences·CIK 0001506251

Citius Pharmaceuticals, Inc., based in Cranford, New Jersey, is a biopharmaceutical company focused on developing and commercializing critical care products, particularly in oncology, anti-infectives for adjunct cancer care, and unique prescription products. The company aims for leading market positions by offering therapeutic products that address unmet medical needs with lower development risk, often by reformulating previously approved drugs with existing safety and efficacy data. This strategy focuses on products with intellectual property and regulatory exclusivity. In December 2025, Citius Pharmaceuticals became a commercial company with the launch of LYMPHIR by its majority-owned subsidiary, Citius Oncology. LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, received FDA approval for treating patients with persistent or recurrent cutaneous T-cell lymphoma ("CTCL"). Citius Pharma in-licensed LYMPHIR in September 2021, and it is now owned by Citius Oncology. The company is also developing three proprietary products: Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation for hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for ARDS. Since its inception, the company has focused on business planning, acquiring technology, research and development, staffing, and raising capital.

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CTXR at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Citius Pharmaceuticals Reports Going Concern, Nasdaq Non-Compliance, and Significant Dilutive Capital Raises

Financial Snapshot

Fiscal year ended September 30, 2025
Net Income
-$39.74M
Diluted EPS
-$3.38
Op. Cash Flow
-$26.55M
Operating Income
-$38.53M
Cash & Equivalents
$4.25M
Debt / Equity
0.00×
Shares Outstanding
18.07M sh
Source: 10-K · filed 2026-01-28 · accession 0001213900-26-008861
$0.5085
52-week range · as of 2026-10-26 $0.3699 – $1.98
Market cap
$13.96M
Volume
183.7K (0.7× avg)
3-mo avg 263.4K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CTXR - Filings & News (Page 2)

CTXR
Feb 13, 2026, 8:00 AM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.8547
Real-time Price: $0.5085 info
Change: -$0.3462 (-41%) info
Market Cap: $13.96M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets